Xie Chenjie,Gu Song,Tian Ruicheng,et al.Treatment and prognostic factors of recurrent wilm’s tumor in children[J].Journal of Clinical Pediatric Surgery,,20():430-436.[doi:10.12260/lcxewkzz.2021.05.007]
Click Copy

Treatment and prognostic factors of recurrent wilm’s tumor in children

Journal of Clinical Pediatric Surgery[ISSN:1671-6353/CN:43-1380/R] volume: 第20卷 Number: 2021 05 Page: 430-436 Column: 儿童肿瘤 Date of publication: 2021-05-25
Author(s):
Xie Chenjie1;  Gu Song1;  Tian Ruicheng1;  Chen Qimin1;  Tang Jingyan2;  Pan Ci2;  Yin Minzhi3;  Zhang Zhongde3;  Xu Min1
1. Department of Surgery, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China;
2. Department of Hematological Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China;
3. Department of Pathology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Keywords:
Wilms tumor; Treatment; Prognosis; Root Cause Analysis; Child
CLC:
R737.11;R730.5
DOI:
10.12260/lcxewkzz.2021.05.007
Abstract:
Objective To explore the treatments and prognostic factors of recurrent Wilm’s tumor in children.Methods From April 2006 to December 2019,23 children of recurrent Wilm’s tumor were analyzed retrospectively,including tumor stage,pathological classification,intraoperative status,postoperative radiotherapy,postoperative recurrence time/site,postoperative treatment and prognosis.Results There were 11 boys and 12 girls with a median onset age of 42(6-109) months.The median recurrence time was 8(3-111) months.During a follow-up period of 29 to 172 months,there were 17 survivors and 6 deaths.No significant difference existed in recurrence time or total survival time between stages Ⅱ and Ⅲ.And there was no significant difference in overall survival time in terms of whether or not primary tumor was FH type,whether or not autologous bone marrow transplantation (ABMT) was performed,whether or not radiotherapy was offered and different recurrence times.Conclusion Tumor stage,FH type,ABMT and radiotherapy are not independent risk factors of total survival time.Close follow-ups,early diagnosis,active reoperation and postoperative chemoradiotherapy improve the survival rate of children with recurrent Wilm’s tumor.

References:

1 Termuhlen AM,Tersak JM,Liu Q,et al.Twenty-five year follow-up of childhood Wilms tumor:a report from the Childhood Cancer Survivor Study[J].Pediatr Blood Cancer,2011,57(7):1210-1216.DOI:10.1002/pbc.23090.
2 Pan C,Cai JY,Xu M,et al.Renal tumor in developing countries:142 cases from a single institution at Shanghai,China[J].World J Pediatr,2015,11(4):326-330.DOI:10.1007/s12519-015-0041-3.
3 张国锋,王家祥.肾母细胞瘤78例临床特点及生存分析[J].中华实用儿科临床杂志,2011,26(9):713-715.DOI:CNKI:SUN:SYQK.0.2011-09-033. Wang GF,Wang JX.Clinical features and survival analysis of nephroblastoma in 78 children[J].J Appl Clin Pediatr,2011,26(9):713-715.DOI:CNKI:SUN:SYQK.0.2011-09-033.
4 Reinhard H,Schmidt A,Furtwangler R,et al.Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies[J].Oncol Rep,2008,20(2):463-467.DOI:10.3892/or_00000029.
5 Grundy P,Breslow N,Green DM,et al.Prognostic factors for children with recurrent Wilms’ tumor:results from the Second and Third National Wilms’ Tumor Study[J].J Clin Oncol,1989,7(5):638-647.DOI:10.1200/JCO.1989.7.5.638.
6 Shamberger RC,Guthrie KA,Ritchey ML,et al.Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4[J].Ann Surg,1999,162(4):1556-1557.DOI:10.1097/00000658-199902000-00019.
7 Aoba T,Urushihara N,Fukumoto K,et al.Relapse of unilateral favorable histology Wilms’ tumor:significant clinicopathological factors[J].J Pediatr Surg,2012,47(12):2210-2215.DOI:10.1016/j.jpedsurg.2012.09.010.
8 Dome JS,Perlman EJ,Graf N.Risk stratification for wilms tumor:current approach and future directions[J].Am Soc Clin Oncol Educ Book,2014:215-223.DOI:10.14694/EdBook_AM.2014.34.215.
9 Dome JS,Fernandez CV,Mullen EA,et al.Children’s Oncology Group’s 2013 blueprint for research:renal tumors[J].Pediatr Blood Cancer,2013,60(6):994-1000.DOI:10.1002/pbc.24419.
10 Pritchard-Jones K,Bergeron C,de Camargo B,et al.Omission of doxorubicin from the treatment of stage Ⅱ-Ⅲ,intermediate-risk Wilms’ tumour (SIOP WT 2001):an open-label,non-inferiority,randomised controlled trial[J].Lancet,2015,386(9999):1156-1164.DOI:10.1016/S0140-6736(14)62395-3.
11 中国抗癌协会小儿肿瘤专业委员会.儿童肾母细胞瘤诊断治疗建议(CCCG-WT-2016)[J].中华儿科杂志,2017,55(2):90-94.DOI:10.3760/cma.j.issn.0578-1310.2017.02.007. Chinese Children Cancer Group,Chinese Anti-Cancer Association:Recommendations on Diagnosing & Treating Wilm’s Tumor in Children (CCCG-WT-2016)[J].Chin J Pediatr,2017,55(2):90-94.DOI:10.3760/cma.j.issn.0578-1310.2017.02.007.
12 Sutow WW,Breslow NE,Palmer NF,et al.Prognosis in children with Wilms’ tumor metastases prior to or following primary treatment:results from the first National Wilms’ Tumor Study (NWTS-1)[J].Am J Clin Oncol,1982,5(4):339-347.DOI:10.1097/00000421-198208000-00001.
13 Shamberger RC,Guthrie KA,Ritchey ML,et al.Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4[J].Ann Surg,1999,229(2):292-297.DOI:10.1097/00000658-199902000-00019.
14 陈嘉波,杨体泉,董昆,等.儿童复发性肾母细胞瘤临床特点和治疗经验[J].中华实用儿科临床杂志,2011,6(21):1682-1684.DOI:10.3969/j.issn.1003-515X.2011.21.024. Chen JB,Yang TQ,Dong K,et al.Clinical characteristics and experience of treatment in children with relapsed Wilms’ Tumor[J].J Appl Clin Pediatr,2011,26(21):1682-1684.DOI:10.3969/j.issn.1003-515X.2011.21.024.
15 Ruys AT,Tanis PJ,Nagtegaal ID,et al.Erratum to:Surgical treatment of renal cell cancer liver metastases:a population-based study[J].Ann Surg Oncol,2014,21(4):784-784.DOI:10.1245/s10434-014-3645-2.
16 Malogolowkin MH,Cotton CA,Green DM,et al.Treatment of Wilms tumor relapsing after initial treatment with vincristine,actinomycin D,and doxorubicin.A report from the National Wilms Tumor Study Group[J].Pediatr Blood Cancer,2008,50(2):236-241.DOI:10.1002/pbc.21267.
17 Spreafico F,Pritchard JK,Malogolowkin MH,et al.Treatment of relapsed wilms tumors:Lessons learned[J].Expert Rev Anticancer Ther,2009,9(12):1807-1815.DOI:10.1586/era.09.159.
18 Illhardt T,Ebinger M,Schwarze CP,et al.Children with relapsed or refractory nephroblastoma:favorable long-term survival after high-dose chemotherapy and autologous stem cell transplantation[J].Klin Padiatr,2014,226(6-7):351-356.DOI:10.1055/s-0034-1390504.
19 Spreafico F,Bisogno G,Collini P,et al.Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy,marrow-ablative chemotherapy,and autologous hematopoietic stem cell support:Experience by the Italian association of pediatric hematology and oncology[J].Pediatric Blood Cancer,2008,51(1):23-28.DOI:10.1002/pbc.21524.
20 Malogolowkin MH,Hemmer MT,Le-Rademacher J,et al.Outcomes following autologous hematopoietic stem cell transplant Transplantation,2017 for patients with relapsed Wilms’ tumor:a CIBMTR retrospective analysis[J].Bone Marrow,52(11):1549-1555.DOI:10.1038/bmt.2017.178.
21 Tam C,Spreafico F,Graf N,et al.An international strategy to determine the role of high dose therapy in recurrent Wilms’ tumour[J].Eur J Cancer,2013,49(1):194-210.DOI:10.1016/j.ejca.2012.07.010.
22 Wilde JC,Lameris W,van Hasselt EH,et al.Challenges and outcome of Wilms’ tumour management in a resource-constrained setting[J].Afr J Paediatr Surg,2010,7(3):159-162.DOI:10.4103/0189-6725.70416.
23 Ehrlich PF.Bilateral Wilms’ tumor:the need to improve outcomes[J].Expert Rev Anticancer The,2009,9(7):963-973.DOI:10.1586/era.09.50.
24 王天怡,潘慈,高怡瑾,等.儿童肾母细胞瘤复发后再治疗长期随访研究[J].中华儿科杂志,2017,55(10):743-747.DOI:10.3760/cma.j.issn.0578-1310.2017.10.006. Wang TY,Pan C,Gao YJ,et al.A long-term follow-up report of pediatric relapsed Wilms tumor after retreatment[J].Chin J Pediatr,2017,55(10):743-747.DOI:10.3760/cma.j.issn.0578-1310.2017.10.006.

Memo

收稿日期:2020-03-22。
基金项目:上海市科学技术委员会项目（编号：17441903200，17411950402）；上海市浦东新区科技发展基金（编号：PKJ2017-Y04）
通讯作者:徐敏,Email:jackxm1236@126.com

Last Update: 1900-01-01